<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01288521</url>
  </required_header>
  <id_info>
    <org_study_id>200806718</org_study_id>
    <nct_id>NCT01288521</nct_id>
  </id_info>
  <brief_title>Pharmacogenetics to Predict Drug Interactions in Kidney Transplant Recipients</brief_title>
  <official_title>Utilizing Pharmacogenetics to Predict Drug Interactions in Kidney Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sony Tuteja</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American College of Clinical Pharmacy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Solid organ transplant recipients would greatly benefit from pharmacogenetic evaluation since
      immunosuppressive drug regimens consist of multiple medications with narrow therapeutic
      ranges and toxic adverse event profiles. Tacrolimus is a potent immunosuppressive agent
      utilized for rejection prophylaxis. Intensive pharmacokinetic monitoring must be performed
      following organ transplantation to ensure therapeutic drug concentrations due to its highly
      variable pharmacokinetics profile and narrow therapeutic index. Tacrolimus is a substrate for
      CYP450 3A and for the membrane transporter p-glycoprotein (Pgp). Polymorphisms in the gene
      encoding for CYP3A5 have been extensively studied and have been found to influence the dosing
      of tacrolimus. The effect of ABCB1 gene polymorphisms (which encodes for Pgp) upon tacrolimus
      pharmacokinetics has been more difficult to establish.

      This study will determine if haplotypes derived from three frequent polymorphisms in the
      ABCB1 gene (C1236T, G2677T, C3435T) can predict the degree of drug interaction between
      tacrolimus (CYP3A5/Pgp substrate) and ketoconazole (CYP3A5/Pgp inhibitor) in patients who are
      CYP3A5 nonexpressors.

      This prospective pharmacokinetic and pharmacogenomic study will enroll 20 stable renal
      transplant recipients with the CYP3A5 *3/*3 genotype and grouped by ABCB1 haplotype (CGC vs
      TTT). Pharmacokinetics of tacrolimus will be assessed on 2 occasions with and without
      ketoconazole coadministration separated by 1 week. The order of study occasions will be
      randomized in a crossover design.

      The results of this study may identify a genomic marker for predicting drug-drug
      interactions. Knowing this information a priori will aid clinicians in modifying drug dosing
      and alleviate patients of the burden of significant drug toxicities.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two mL of blood will be obtained for pharmacogenomic screening for CYP3A5 and ABCB1
      genotypes. Patients with the CYP3A5*3/*3 genotype will be consented for the pharmacokinetic
      portion of the study. Volunteers from this patient cohort will participate in 2 overnight
      visits to the General Clinical Research Center (GCRC).

      Patients will report to the GCRC on the evening before each study visit. They will be
      required to fast from midnight the night before until 1 hour after tacrolimus administration,
      which will be in the morning approximately at 8 am.

      Pharmacokinetics of tacrolimus will be assessed on 2 occasions with and without ketoconazole
      coadministration separated by 1 week. The order of study occasions will be randomized in a
      crossover design. Each patient will take their take their usual oral dose of tacrolimus and
      have whole blood levels obtained immediately before (C0) and at 0.5, 1, 1.5, 2, 3, 4, 6 hours
      after the tacrolimus dose. They will then receive tacrolimus by intravenous infusion, a
      therapeutic dose over four hours. The IV dose will take the place of the patients' usual
      evening dose of tacrolimus. Additional blood will be drawn for tacrolimus at 0.25, 0.5, 1,
      1.5, 2, 3, 4, 6, 8, 12, 18 hours after the intravenous dose. During the ketoconazole visit,
      tacrolimus doses will be decreased by one-half to account for the drug interaction and avoid
      potential tacrolimus-induced toxicities. Ketoconazole 200 mg will be administered orally
      every 12 hours for a total of 3 doses; the first ketoconazole dose will be given 13 hours
      before tacrolimus administration.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tacrolimus Bioavailability (F)</measure>
    <time_frame>baseline and 2 weeks</time_frame>
    <description>Tac bioavailability alone vs. Tac bioavailability with Keto. To determine F we took the ratio of area under the curve of the oral dose divided by the area under the curve of the IV dose. F was determined by fitting a model that considered the plasma concentration of tac with IV vs. oral dosing.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>Tacrolimus + Ketoconazole, Then Tacrolimus alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants first received tacrolimus in combination with with ketoconazole. After a 1-2 week washout they received tacrolimus alone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tacrolimus alone, Then Tacrolimus + Ketoconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants first received tacrolimus alone. After a 1-2 week washout period they received tacrolimus in combination with ketoconazole.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus + Ketoconazole, Then Tacrolimus alone</intervention_name>
    <description>Pharmacokinetic profiling of tacrolimus (AUC0-24h) in subjects receiving tacrolimus + ketoconazole 200 mg every 12 hours x 3 doses.</description>
    <arm_group_label>Tacrolimus + Ketoconazole, Then Tacrolimus alone</arm_group_label>
    <other_name>Tacrolimus</other_name>
    <other_name>Ketoconazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus alone, Then Tacrolimus + Ketoconazole</intervention_name>
    <description>Pharmacokinetic profiling of subjects on a stable dose of tacrolimus (AUC 0-24h)</description>
    <arm_group_label>Tacrolimus alone, Then Tacrolimus + Ketoconazole</arm_group_label>
    <other_name>Tacrolimus</other_name>
    <other_name>Ketoconazole</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Kidney transplant recipient

          -  &gt; 6 months posttransplant

          -  Serum creatinine &lt; 1.6 mg/dL

          -  Currently taking a stable dose of tacrolims

        Exclusion Criteria:

          -  On medications known to interact with tacrolimus or ketoconazole

          -  Multi-organ transplant recipient

          -  Serum creatinine &gt;1.5 mg/dL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sony Tuteja, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2010</study_first_submitted>
  <study_first_submitted_qc>January 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2011</study_first_posted>
  <results_first_submitted>March 31, 2017</results_first_submitted>
  <results_first_submitted_qc>February 22, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 9, 2018</results_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Sony Tuteja</investigator_full_name>
    <investigator_title>Associate</investigator_title>
  </responsible_party>
  <keyword>kidney transplantation</keyword>
  <keyword>tacrolimus</keyword>
  <keyword>P-glycoprotein</keyword>
  <keyword>ABCB1</keyword>
  <keyword>genotyping</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Ketoconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Kidney transplant recipients were recruited from the transplant clinic from 10/2008 to 6/2010.</recruitment_details>
      <pre_assignment_details>Assignment to the treatment group was based on CYP3A5 genotype and subjects were eligible only if they had the *3/*3 genotype. 22 subjects were consented to participate. Based on genotype, 3 subjects were ineligible to complete the study. Of the 19 eligible subjects, 11 declined to participate. 8 subjects completed the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tacrolimus + Ketoconazole, Then Tacrolimus Alone</title>
          <description>Randomized, cross over design
Tacrolimus + Ketoconazole : Pharmacokinetic profiling of tacrolimus (AUC0-24h) in subjects receiving tacrolimus + keotconazole 200 mg every 12 hours x 3 doses.
Tacrolimus alone : Pharmacokinetic profiling of subjects on a stable dose of tacrolimus (AUC 0-24h)</description>
        </group>
        <group group_id="P2">
          <title>Tacrolimus Alone, Then Tacrolimus + Ketoconazole</title>
          <description>Randomized, cross over design
Tacrolimus + Ketoconazole : Pharmacokinetic profiling of tacrolimus (AUC0-24h) in subjects receiving tacrolimus + keotconazole 200 mg every 12 hours x 3 doses.
Tacrolimus alone : Pharmacokinetic profiling of subjects on a stable dose of tacrolimus (AUC 0-24h)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tacrolimus + Ketoconazole, Then Tacrolimus Alone</title>
          <description>Randomized, cross over design
Tacrolimus + Ketoconazole : Pharmacokinetic profiling of tacrolimus (AUC0-24h) in subjects receiving tacrolimus + keotconazole 200 mg every 12 hours x 3 doses.
Tacrolimus alone : Pharmacokinetic profiling of subjects on a stable dose of tacrolimus (AUC 0-24h)</description>
        </group>
        <group group_id="B2">
          <title>Tacrolimus Alone, Then Tacrolimus + Ketoconazole</title>
          <description>Randomized, cross over design
Tacrolimus + Ketoconazole : Pharmacokinetic profiling of tacrolimus (AUC0-24h) in subjects receiving tacrolimus + keotconazole 200 mg every 12 hours x 3 doses.
Tacrolimus alone : Pharmacokinetic profiling of subjects on a stable dose of tacrolimus (AUC 0-24h)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Information gathered through self-report and medical records review</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" spread="12.5"/>
                    <measurement group_id="B2" value="57" spread="5.5"/>
                    <measurement group_id="B3" value="55.6" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tacrolimus Bioavailability (F)</title>
        <description>Tac bioavailability alone vs. Tac bioavailability with Keto. To determine F we took the ratio of area under the curve of the oral dose divided by the area under the curve of the IV dose. F was determined by fitting a model that considered the plasma concentration of tac with IV vs. oral dosing.</description>
        <time_frame>baseline and 2 weeks</time_frame>
        <population>Stable kidney transplant recipients</population>
        <group_list>
          <group group_id="O1">
            <title>Tacrolimus Alone</title>
            <description>cross over design
Tacrolimus alone : Pharmacokinetic profiling of subjects on a stable dose of tacrolimus (AUC 0-24h)</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus + Ketoconazole</title>
            <description>Tacrolimus + Ketoconazole : Pharmacokinetic profiling of tacrolimus (AUC0-24h) in subjects receiving tacrolimus + keotconazole 200 mg every 12 hours x 3 doses.</description>
          </group>
        </group_list>
        <measure>
          <title>Tacrolimus Bioavailability (F)</title>
          <description>Tac bioavailability alone vs. Tac bioavailability with Keto. To determine F we took the ratio of area under the curve of the oral dose divided by the area under the curve of the IV dose. F was determined by fitting a model that considered the plasma concentration of tac with IV vs. oral dosing.</description>
          <population>Stable kidney transplant recipients</population>
          <units>ratio of oral to IV</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.224" spread="0.107"/>
                    <measurement group_id="O2" value="0.681" spread="0.308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The bioavailability of Tac alone vs. Tac +keto was compared using a general linear model including sex and creatinine clearance as covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The null hypothesis is that the tacrolimus biovailability alone is equal to the tacrolimus bioavailability when given with ketoconazole.</non_inferiority_desc>
            <p_value>0.006</p_value>
            <method>Regression, Linear</method>
            <method_desc>The bioavailability with Tac alone vs. Tac +keto was compared using linear model adjusting for sex and creatinine clearance.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Data collected over 6 months of the PK intervention</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tacrolimus Alone</title>
          <description>Tacrolimus alone : Pharmacokinetic profiling of subjects on a stable dose of tacrolimus (AUC 0-24h)</description>
        </group>
        <group group_id="E2">
          <title>Tacrolimus + Ketoconazole</title>
          <description>Tacrolimus + Ketoconazole : Pharmacokinetic profiling of tacrolimus (AUC0-24h) in subjects receiving tacrolimus + keotconazole 200 mg every 12 hours x 3 doses.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to small numbers of subjects analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Sony Tuteja, Pharmd</name_or_title>
      <organization>University of Iowa</organization>
      <phone>215-573-7834</phone>
      <email>sony.tuteja@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

